Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01806064
Title A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tracon Pharmaceuticals Inc.
Indications

renal cell carcinoma

Therapies

Bevacizumab + Carotuximab

Age Groups: adult
Covered Countries USA


No variant requirements are available.